EMB-001 Sales Forecast

Key Factors Driving EMB-001 Growth

First-in-Class Therapy in Cocaine Use Disorder (CUD)

• No FDA-approved pharmacotherapies currently exist for CUD
• Behavioral therapy remains the standard of care

Implication:

• EMB-001 has a clear first-mover advantage
• Opportunity to define:
• Treatment paradigm
• Pricing and reimbursement
• High likelihood of rapid adoption if efficacy is confirmed

Novel Mechanism Targeting Stress-Response Pathway

• EMB-001 combines:
• Metyrapone (cortisol synthesis inhibitor)
• Oxazepam (benzodiazepine)
• Mechanism:
• Modulates stress-response system (HPA axis)
• Reduces stress- and cue-induced relapse triggers

Promising Clinical Efficacy Signals (Proof-of-Concept Established)

Pilot Clinical Study (Published)

• Significant reduction in cocaine use vs placebo
• Reduced craving over 6 weeks

Phase 1b (Cocaine Interaction Study)

• Well tolerated with no serious adverse events
• No increase in cocaine exposure when co-administered
• 93% adverse events mild

Biomarker Evidence

• Demonstrated blunting of cortisol response to cocaine, supporting mechanism

Advancement into Phase II (Mid-Stage Validation)

• Phase II randomized, placebo-controlled study:
• ~80 patients with moderate–severe CUD
• 12–13 week treatment duration

Favorable Safety & Real-World Usability

• No serious adverse events reported in early studies
• Components are already FDA-approved drugs:
• Known safety profiles
• Reduced regulatory uncertainty

Large and Growing Target Population

• ~1.8 million diagnosed CUD cases in major markets (7MM)
• ~18.2 million cocaine users globally

Market dynamics:

• Increasing prevalence
• High relapse rates
• Limited treatment success

EMB-001 Recent Developments

In December 2019, Embera NeuroTherapeutics announced completion of its Series B financing and the receipt of two grant awards which will fund Phase II clinical studies for EMB-001 in cocaine use disorder and smoking cessation. EMB-001 is designed to help patients struggling with addiction to maintain abstinence and improve their quality of life by simultaneously targeting multiple neurological pathways that play a role in stress-induced, cue-induced and drug-induced addiction relapse.

“EMB-001 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of EMB-001 for potential indication like Smoking withdrawal and Cocaine-related disorders in the 7MM. A detailed picture of EMB-001’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the EMB-001 for potential indications. The EMB-001 market report provides insights about EMB-001’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current EMB-001 performance, future market assessments inclusive of the EMB-001 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of EMB-001 sales forecasts, along with factors driving its market.

EMB-001 Drug Summary

EMB-001 is a patented, first-in-class combination product from Embera NeuroTherapeutics comprising two FDA-approved drugs: the cortisol synthesis inhibitor metyrapone (Metopirone) and the benzodiazepine receptor agonist oxazepam, designed as an oral therapy to target the stress response system implicated in addiction and relapse. It reduces stress-induced hyperactivity in the hypothalamic-pituitary-adrenal axis triggered by drug cues, thereby potentially decreasing cravings and loss of control in substance use disorders including cocaine, nicotine, methamphetamine, and tobacco use disorders, with a novel mechanism distinct from existing treatments. Phase I trials (e.g., NCT02406066, NCT02856854) confirmed safety, tolerability, and pharmacokinetics at low doses, while a Phase Ib cocaine interaction study showed no new safety signals when co-administered with cocaine; preclinical and pilot human data support efficacy in reducing addiction behaviors, with plans for Phase II advancement in cocaine and tobacco use disorders, though development appears stalled since around 2017. The report provides EMB-001’s sales, growth barriers and drivers, post usage and approvals in multiple indications. 

Scope of the EMB-001 Market Report

The report provides insights into:

• A comprehensive product overview including the EMB-001 MoA, description, dosage and administration, research and development activities in potential indication like Smoking withdrawal and Cocaine-related disorders.
• Elaborated details on EMB-001 regulatory milestones and other development activities have been provided in EMB-001 market report.
• The report also highlights EMB-001‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The EMB-001 market report also covers the patents information, generic entry and impact on cost cut.
• The EMB-001 market report contains current and forecasted EMB-001 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The EMB-001 market report also features the SWOT analysis with analyst views for EMB-001 in potential indications.

Methodology

The EMB-001 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EMB-001 Analytical Perspective by DelveInsight

• In-depth EMB-001 Market Assessment

This EMB-001 sales market forecast report provides a detailed market assessment of EMB-001 for potential indication like Smoking withdrawal and Cocaine-related disorders in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted EMB-001 sales data uptil 2034.

• EMB-001 Clinical Assessment

The EMB-001 market report provides the clinical trials information of EMB-001 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

EMB-001 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

EMB-001 Market Potential & Revenue Forecast

• Projected market size for the EMB-001 and its key indications
• Estimated EMB-001 sales potential (EMB-001 peak sales forecasts)
• EMB-001 Pricing strategies and reimbursement landscape

EMB-001 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• EMB-001 Market positioning compared to existing treatments
• EMB-001 Strengths & weaknesses relative to competitors

EMB-001 Regulatory & Commercial Milestones

• EMB-001 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

EMB-001 Clinical Differentiation

• EMB-001 Efficacy & safety advantages over existing drugs
• EMB-001 Unique selling points

EMB-001 Market Report Highlights

• In the coming years, the EMB-001 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The EMB-001 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EMB-001’s dominance.
• Other emerging products for Smoking withdrawal and Cocaine-related disorders are expected to give tough market competition to EMB-001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EMB-001 in potential indications.
• Analyse EMB-001 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted EMB-001 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of EMB-001 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of EMB-001? How strong is EMB-001’s clinical and commercial performance?
• What is EMB-001’s clinical trial status in each individual indications such as Smoking withdrawal and Cocaine-related disorders and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EMB-001 Manufacturers?
• What are the key designations that have been granted to EMB-001 for potential indications? How are they going to impact EMB-001’s penetration in various geographies?
• What is the current and forecasted EMB-001 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of EMB-001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to EMB-001 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• ·       How cost-effective is EMB-001? What is the duration of therapy and what are the geographical variations in cost per patient?